<DOC>
	<DOCNO>NCT02780180</DOCNO>
	<brief_summary>Heart Failure ( HF ) common clinical condition characterize either heart pump sufficiently become stiff . A variety mechanism contribute progressive cardiac remodel dysfunction . A new therapeutic approach prevent activation brain neuromodulatory pathway , may lead improve HF . QCG001 prodrug EC33 , aminopeptidase A ( APA ) inhibitor . QCG001 show antihypertensive agent animal model . This study investigate safety efficacy QGC001 HF patient .</brief_summary>
	<brief_title>QUantum Genomics Incremental Dosing Heart Failure - QUID-HF</brief_title>
	<detailed_description>Despite advance care , prognosis remain poor overt Heart Failure ( HF ) develop . HF common clinical condition characterize either heart pump sufficiently become stiff associate higher incidence patient illness death case . A variety mechanism contribute progressive cardiac remodel dysfunction . A new therapeutic approach prevent activation brain neuromodulatory pathway , may lead improve HF . QCG001 prodrug EC33 , specific selective aminopeptidase A ( APA ) inhibitor . QCG001 show antihypertensive agent animal model . This study investigate safety efficacy QGC001 up-titrated form 50mg twice daily maximum 500 mg twice daily , patient worsen chronic HF 28 day 7 day discontinuation ( day 35 ) . 6 European country involve study ( France , Netherlands , Germany , Norway , Poland United Kingdom ) include 10 investigational hospital . Patients would follow 35 day inclusion period last 10 month .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>A sign date informed consent form prior study procedure Adult male subject female subject without childbearing potential ≤ 80 year Clinical diagnosis WHF , New York Heart Association ( NYHA ) class II III least 3 month prior emergency presentation hospital . Eligible subject must enrol short discharge within 8 day discharge episode decompensated HF ( index event ) define 1. overnight stay hospital , emergency department , medical observation facility capability treat intravenous medication observe HF patient , 2. unscheduled outpatient visit HF management centre , parenteral therapy require HF stabilization . Documented leave ventricular ejection fraction ( LVEF ) 40 % measure modality within previous 6 month subject 's medical history Subjects must also least one local measurement BNP level ≥ 400 pg/mL NTproBNP level ≥1600 pg/mL ( preferred assay , local lab ) time index hospitalization randomisation . eGFR &gt; 60 mL/min/1.73 m2 ( MDRD ) screen No decrease eGFR great 20 % admission index hospitalisation randomisation day . Serum potassium 5.0 mmol/L screen Systolic blood pressure 120 mmHg ( average 3 consecutive measurement ) Prescribed optimal pharmacologic therapy per ESC guideline diagnosis treatment acute chronic heart failure 2012 '' , base updated current clinical practice , unless contraindicate nottolerated , stable dose ( e.g. , recommend double decrease dosage ) least 30 day prior enrolment . Taking oral loop diuretic dose &lt; 250 mg furosemide daily ( equivalent ) Age &gt; 80 year BMI &gt; 35kg.m2 Patients require use HF IV therapy oral furosemide &gt; 250 mg ( equivalent ) time 48 hour immediately randomisation . Patients unstable angina , myocardial infarction , PTCA , coronary artery bypass graft , cerebral vascular accident , transient ischemic attack within previous 3 month ( 90 day ) enrolment . Patients whose primary cause heart failure mitral aortic valve disease congenital heart disease hypertrophic obstructive cardiomyopathy infiltrative cardiomyopathy ( e.g . amyloidosis , sarcoidosis ) myocarditis . Patients permanent atrial fibrillation ( AF ) ( per `` ACC/AHA/ESC 2006 guideline management patient AF '' ) within 3 month ( 90days ) prior enrolment Patients schedule Pacemaker ( include ICD , CRT ) , Angioplasty , CABG LVAD within next 3 month Patients document chronic obstructive lung disease . eGFR &lt; 60 mL/min/1.73 m2 ( MDRD ) screen Decrease eGFR great 20 % admission index hospitalisation randomisation day Serum potassium &gt; 5.0 mmol/L screen Systolic blood pressure &lt; 120 mmHg sign symptom hypotension Symptomatic hypotension orthostatic hypotension define decrease 30 mm Hg stand vs. sit position screen T0 D0 ( take study medication ) Insulinrequiring diabetic patient ( include type 1 Diabetes ) HbA1c ≥ 10 % screen visit History angioneurotic edema Patients life expectancy le 12 month per physician judgment Patients involve clinical study Patients take investigational nonapproved treatment Women childbearing potential might pregnant time study ( method assessment upon physician 's discretion ) Patients prior cardiac transplant patient currently list cardiac transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Aminopeptidase A inhibitor</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Up-titration</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Patient Safety</keyword>
	<keyword>Treatment Efficacy</keyword>
</DOC>